Oncotarget

Case Reports:

Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature

Xin Li, Shijiang Xing and Qiumei Dong _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:55760-55765. https://doi.org/10.18632/oncotarget.17406

Metrics: PDF 1166 views  |   HTML 2351 views  |   ?  


Abstract

Xin Li1, Shijiang Xing1 and Qiumei Dong2

1Department of Medical Oncology, Xiaolan People's Hospital Affiliated to Southern Medical University, Zhongshan, China

2Department of Medical Oncology, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

Correspondence to:

Qiumei Dong, email: [email protected]

Keywords: Down syndrome, non-small-cell lung cancer, EGFR mutation, trisomy 21, EGFR-TKIs resistance

Received: February 07, 2017    Accepted: April 03, 2017    Published: April 25, 2017

ABSTRACT

Background: Solid tumors have a markedly decreased incidence in individuals with Down syndrome (DS), including lung cancers.

Methods: The clinical presentation of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) in DS was reported and literature on the subject reviewed.

Results: In individuals with DS, the risk of lung cancer appears markedly lower. EGFR mutation and EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance also exist in DS with lung cancer.

Conclusions: Clinicians should consider EGFR mutation and EGFR-TKIs resistance in lung cancer patients with DS.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17406